X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

Content Team by Content Team
5th November 2022
in Drug Development, News
$2 Million Gene Therapy Might Become The Standard In The US

In recent years, the high cost of gene therapies has emerged as a major barrier to the development of personalised medicines. Most notably, bluebird Bio was forced to pull its blood disorder medicine Zynteglo from the European market after encountering an unworkable pricing situation in the region.

However, the one-time beta-thalassemia therapy price charged by bluebird in the EU, which was initially offered at $1.8 million in June 2019, may start to be accepted in the United States. That’s the low end, too.

A report on the clinical efficacy and economics of CSL Behring’s etranacogene dezaparvovec for haemophilia B was released by the Institute for Clinical and Economic Review (ICER) on November 2. The U.S. drug cost watchdog also revised its prior assessment of BioMarin’s valoctocogene roxaparvovec, which recently won approval in Europe as Roctavian, for haemophilia A.

According to the ICER evaluation, CSL’s medication, which is scheduled for an FDA priority review decision at the end of November, would be fairly priced at around $2.9 million. The business resubmitted BioMarin’s Roctavian to the U.S. FDA in late September at a price of about $1.9 million, which would be acceptable. ICER warned in a release that duration of effectiveness with gene treatments and risks for uncommon side events remain important concerns.

Before a virtual public meeting on November 18, where an ICER committee will assess the evidence on the medications and hear additional testimony, the watchdog’s review will be conducted. The specialists will also discuss the treatments’ relative efficacy as well as their additional advantages and long-term worth.

ICER, however, mostly supported the high million-dollar price stickers for both BioMarin’s and CSL’s medications in its own study. Due to the absence of the necessity for relatively expensive preventative treatment, both medicines exhibit health improvements and the possibility of significant cost offsets. Roctavian’s net price in Europe is approximately 1.5 million euros (or $1.46 million), according to BioMarin this summer. The drug would still be sensibly valued at up to $1.9 million, according to ICER’s most recent estimate, although BioMarin might go as high as $2.5 million.

According to BioMarin, the company anticipates making its first commercial Roctavian sales in Europe in the fourth quarter. The U.S. FDA authorised bluebird’s $2.8 million medication Zynteglo in August, and the firm thinks the high price reflects the benefit of a one-time treatment in the U.S., according to the company’s chief commercial officer, Tom Klima, in an interview earlier this year.

In addition, shortly after Zynteglo received permission in the United States, bluebird in September successfully obtained approval for eli-cel, which is now known as Skysona, for the extremely uncommon neurological condition cerebral adrenoleukodystrophy (CALD). While there is little doubt that gene treatments are transforming the landscape of cancer and rare illness treatment, Brett Sahli, Prime Therapeutics’ assistant vice president of pharmaceutical trade affairs, warned that there is always a risk of cost shocks.

Pricing for therapies in the millions of dollars makes access impossible in many places, Pearson said, unless it’s on a totally compassionate basis or another basis outside the developed countries. The dilemma is even greater globally, ICER president Steven Pearson, M.D., M.Sc., said on the panel, noting gene therapy is still a fairly dicey business proposition for companies in the field.

Previous Post

Cancer Medicine Prices Jump 53% In Five Years In The U.S

Next Post

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

Related Posts

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Next Post

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In